文献速递乳腺癌放疗

21基因复发评分在预测T1N0乳腺癌保乳术后放疗预后获益中的作用

Role of 21-Gene Recurrence Score in Predicting Prognostic Benefit of Radiation Therapy After Breast-Conserving Surgery for T1N0 Breast Cancer.
PubMed 文献 · Pract Radiat Oncol · 2022-08-28

该研究基于美国国家癌症数据库(2004-2017)分析79,040例pT1N0雌激素受体阳性、孕激素受体阳性、人表皮生长因子受体2阴性且接受保乳术的乳腺癌患者,按21基因复发评分分为低危(1-10)、中危(11-25)、高危(26-100)三层,经倾向性评分匹配后比较放疗与未放疗的总生存。中危和高危组放疗与更好总生存相关,低危组无显著获益。

要点

  • 中危复发评分组5年总生存放疗95% vs 未放疗93%(P=0.001)。
  • 高危复发评分组5年总生存放疗95% vs 未放疗84%(P<0.001)。
  • 低危复发评分组5年总生存放疗95% vs 未放疗93%(P=0.184),无显著差异。

核心结论

  • 中危或高危复发评分患者接受放疗观察到总生存获益,低危复发评分患者未观察到总生存获益。
  • 作者认为需要未来前瞻性评估。

研究设计与样本

  • 查询美国国家癌症数据库(2004-2017)女性pT1N0雌激素受体阳性、孕激素受体阳性、人表皮生长因子受体2阴性且接受保乳术并有可用复发评分的乳腺癌患者。
  • 按复发评分分层:低危1-10、中危11-25、高危26-100,每个队列内进行倾向性评分匹配创建1:1放疗与未放疗匹配队列。
  • 采用Kaplan-Meier分析评估总生存,采用单变量和多变量Cox比例风险分析识别总生存的临床和治疗预后因素。

主要发现

  • 共79,040例患者符合标准:低危队列18,823例,中危队列52,341例,高危队列7,876例。
  • 总计92%患者接受放疗:低危队列91%,中危队列93%,高危队列92%。
  • 倾向性评分匹配后,低危队列5年总生存放疗95% vs 未放疗93%(P=0.184)。
  • 中危队列5年总生存放疗95% vs 未放疗93%(P=0.001)。
  • 高危队列5年总生存放疗95% vs 未放疗84%(P<0.001)。

关键数值与推荐

  • 多变量分析显示放疗是中危队列(P=0.001)和高危队列(P<0.001)总生存的正面预后因素。
  • 低危队列多变量分析中放疗(P=0.186)不能预测总生存改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要未来前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 21-gene RT-PCR recurrence score (RS) is performed in patients with hormone receptor-positive (ER+, PR+), human epidermal growth factor receptor 2 (HER2)-negative, N0 breast cancer to determine which patients will likely benefit from chemotherapy after breast-conserving surgery (BCS). The purpose of this study was to evaluate whether the RS can predict for patients likely to benefit from radiation therapy (RT) after BCS. METHODS AND MATERIALS: The National Cancer Database was queried (2004-2017) for female patients with pT1N0 ER+ PR+ HER2-negative breast cancer treated with BCS who had an available RS. Patients were stratified based on their RS (low risk [LR], 1-10; intermediate risk [IR], 11-25; high risk [HR], 26-100). For each RS cohort, propensity score matching was conducted to create 1:1 matched cohorts of patients who received RT and patients who did not. Kaplan-Meier analysis evaluated overall survival (OS). Univariable and multivariable (MVA) Cox proportional hazard analysis identified clinical and treatment factors prognostic for OS. RESULTS: A total of 79,040 patients met the selection criteria: 18,823 in the LR cohort, 52,341 in the IR cohort, and 7876 in the HR cohort. A total of 92% of patients received RT: 91% in the LR cohort, 93% in the IR cohort, and 92% in the HR cohort. After propensity score matching, the 5-year OS in the LR cohort was 95% for those who received RT and 93% for those who did not (P = .184). In the IR cohort, the 5-year OS was 95% for those who received RT and 93% for those who did not (P = .001). In the HR cohort, the 5-year OS was 95% for those who received RT and 84% for those who did not (P < .001). MVA demonstrated that RT was a positive prognostic factor for OS in both the IR cohort (P = .001) and HR cohort (P < .001). On MVA in the LR cohort, RT (P = .186) was not predictive of improved OS. CONCLUSIONS: An OS benefit was observed with the use of RT in patients with IR or HR RS but not in patients with LR RS. Future prospective evaluation is warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chevli N, Haque W, Tran KT, et al. Role of 21-Gene Recurrence Score in Predicting Prognostic Benefit of Radiation Therapy After Breast-Conserving Surgery for T1N0 Breast Cancer. Pract Radiat Oncol. 2022. PMID: 36038115. doi:10.1016/j.prro.2022.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。